BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Staging
10 results:

  • 1. Risk subtyping and prognostic assessment of prostate cancer based on consensus genes.
    Meng J; Guan Y; Wang B; Chen L; Chen J; Zhang M; Liang C
    Commun Biol; 2022 Mar; 5(1):233. PubMed ID: 35293897
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy.
    Hauth E; Hohmuth H; Cozub-Poetica C; Bernand S; Beer M; Jaeger H
    Br J Radiol; 2015 Oct; 88(1054):20150422. PubMed ID: 26268144
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.
    Li S; Ma Y; Xie C; Wu Z; Kang Z; Fang Z; Su B; Guan M
    Oncotarget; 2015 Sep; 6(26):22587-97. PubMed ID: 26041887
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. What is the optimal management of Gleason score 7 prostate cancer at biopsy? A comparison of disease control for prostatectomy versus radiotherapy.
    Watkins JM; Watkins PL; Dufan TA; Koleilat N
    Clin Genitourin Cancer; 2015 Apr; 13(2):e73-7. PubMed ID: 25458369
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. akt1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.
    Priolo C; Pyne S; Rose J; Regan ER; Zadra G; Photopoulos C; Cacciatore S; Schultz D; Scaglia N; McDunn J; De Marzo AM; Loda M
    Cancer Res; 2014 Dec; 74(24):7198-204. PubMed ID: 25322691
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Assessment of required nodal yield in a high risk cohort undergoing extended pelvic lymphadenectomy in robotic-assisted radical prostatectomy and its impact on functional outcomes.
    Sagalovich D; Calaway A; Srivastava A; Sooriakumaran P; Tewari AK
    BJU Int; 2013 Jan; 111(1):85-94. PubMed ID: 22823452
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography.
    Wang Z; Hsieh TC; Zhang Z; Ma Y; Wu JM
    Biochem Biophys Res Commun; 2004 Oct; 323(3):743-9. PubMed ID: 15381063
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.